I-Mab ADR (IMAB)

Jan 8, 2025, 7:00 AM EST - 22 days ago

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Jan 6, 2025, 7:00 AM EST - 24 days ago

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Nov 21, 2024, 7:00 AM EST - 2 months ago

I-Mab to Participate at the Piper Sandler Healthcare Conference

Nov 14, 2024, 7:00 AM EST - 2 months ago

I-Mab Reports Third Quarter 2024 Results

Nov 6, 2024, 7:00 AM EST - 3 months ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Oct 31, 2024, 7:00 AM EDT - 3 months ago

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Oct 30, 2024, 7:00 AM EDT - 3 months ago

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

Oct 28, 2024, 7:00 AM EDT - 3 months ago

I-Mab to Participate at the Truist Securities BioPharma Symposium

Sep 16, 2024, 4:01 PM EDT - 4 months ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 10, 2024, 7:00 AM EDT - 5 months ago

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

Aug 28, 2024, 11:50 AM EDT - 5 months ago

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

Aug 28, 2024, 7:00 AM EDT - 5 months ago

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Aug 26, 2024, 7:00 AM EDT - 5 months ago

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 7:00 AM EDT - 6 months ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 7, 2024, 7:00 AM EDT - 6 months ago

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Jul 15, 2024, 7:30 AM EDT - 7 months ago

I-Mab Announces Leadership Transitions

Jun 5, 2024, 7:00 AM EDT - 8 months ago

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

BMY

May 23, 2024, 5:05 PM EDT - 9 months ago

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

May 22, 2024, 7:00 AM EDT - 9 months ago

I-Mab to Participate at the Jefferies Global Healthcare Conference

Apr 30, 2024, 7:00 AM EDT - 9 months ago

I-MAB Filed 2023 Annual Report on Form 20-F

Apr 5, 2024, 7:00 AM EDT - 10 months ago

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 4:01 PM EDT - 10 months ago

I-Mab Announces Closing of the Divestiture of Business Operations in China

Mar 14, 2024, 5:00 PM EDT - 11 months ago

I-Mab Reports Full Year 2023 Financial Results and Business Update

Feb 18, 2024, 3:28 AM EST - 1 year ago

I-Mab: Trading Below Net Cash With Multiple Upside Options

Feb 7, 2024, 8:36 AM EST - 1 year ago

Biotech firm I-Mab to divest China operations, shift focus to US

Feb 7, 2024, 6:00 AM EST - 1 year ago

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Nov 6, 2023, 8:00 AM EST - 1 year ago

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

Nov 1, 2023, 8:00 AM EDT - 1 year ago

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

Oct 16, 2023, 8:00 AM EDT - 1 year ago

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Oct 10, 2023, 8:00 AM EDT - 1 year ago

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

Sep 22, 2023, 5:09 PM EDT - 1 year ago

AbbVie terminates deal with I-Mab to develop cancer drug

ABBV

Sep 13, 2023, 4:59 PM EDT - 1 year ago

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Sep 5, 2023, 8:00 AM EDT - 1 year ago

I-Mab Announces Upcoming Participation at September Conferences

Aug 17, 2023, 12:26 PM EDT - 1 year ago

I-Mab (IMAB) Q2 2023 Earnings Call Transcript

Aug 17, 2023, 6:00 AM EDT - 1 year ago

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Aug 8, 2023, 8:00 AM EDT - 1 year ago

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

Jul 5, 2023, 8:00 AM EDT - 1 year ago

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

Jun 22, 2023, 8:00 AM EDT - 1 year ago

I-Mab Announces the Appointment of Raj Kannan as CEO

May 25, 2023, 5:01 PM EDT - 1 year ago

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

May 1, 2023, 8:00 AM EDT - 1 year ago

I-MAB Filed 2022 Annual Report on Form 20-F

Apr 26, 2023, 9:16 AM EDT - 1 year ago

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

Apr 25, 2023, 1:46 AM EDT - 1 year ago

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Apr 24, 2023, 9:00 AM EDT - 1 year ago

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

Mar 31, 2023, 11:52 AM EDT - 1 year ago

I-Mab (IMAB) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 6:30 AM EDT - 1 year ago

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

Mar 20, 2023, 8:00 AM EDT - 2 years ago

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

Mar 7, 2023, 8:02 AM EST - 2 years ago

MSCI ESG Updated I-Mab to "A" Rating

Nov 3, 2022, 9:01 AM EDT - 2 years ago

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

Oct 10, 2022, 10:14 AM EDT - 2 years ago

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm